Madrigal Pharmaceuticals, Inc. (MDGL) Earnings History
Net Loss23 years of earnings data (2003–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Madrigal Pharmaceuticals, Inc. (MDGL) Earnings Overview
As of June 22, 2026, Madrigal Pharmaceuticals, Inc. (MDGL) reported trailing twelve-month net income of -$309M, reflecting +41.3% year-over-year growth. The company earned $-10.66 per diluted share over the past four quarters, with a net profit margin of -30.1%.
Looking at the long-term picture, MDGL's historical earnings data spans multiple years. The company achieved its highest annual net income of $79M in fiscal 2009.
Madrigal Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AKRO (-$293M net income), HIMS (-$13M net income, 5.5% margin), ELVN (-$99M net income), MDGL has comparable earnings metrics. Compare MDGL vs AKRO →
MDGL Earnings vs Peers
Earnings metrics vs comparable public companies
MDGL Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$288M | +38.1% | -$300M | $-12.85 | -30.1% | -31.3% |
| 2024 | -$466M | -24.7% | -$498M | $-21.90 | -258.6% | -276.4% |
| 2023 | -$374M | -26.5% | -$380M | $-19.99 | - | - |
| 2022 | -$295M | -22.1% | -$294M | $-17.23 | - | - |
| 2021 | -$242M | -19.6% | -$242M | $-14.63 | - | - |
| 2020 | -$202M | -140.9% | -$206M | $-13.09 | - | - |
| 2019 | -$84M | -155.9% | -$95M | $-4.73 | - | - |
| 2018 | -$33M | -5.3% | -$40M | $-2.22 | - | - |
| 2017 | -$31M | -18.1% | -$32M | $-2.54 | - | - |
| 2016 | -$26M | -285.5% | -$25M | $-5.07 | - | - |
| 2015 | -$7M | +92.1% | -$3M | $-401.56 | - | - |
| 2014 | -$86M | +4.5% | -$84M | $-30.62 | - | - |
| 2013 | -$90M | -43.6% | -$88M | $-44.48 | - | - |
| 2012 | -$63M | -32.5% | -$61M | $-36.99 | - | - |
| 2011 | -$47M | -26.5% | -$45M | $-35.14 | -624.7% | -599.1% |
| 2010 | -$37M | -147.4% | -$37M | $-32.49 | -253.1% | -249.3% |
| 2009 | $79M | +185.4% | $81M | $81.20 | 54.8% | 55.8% |
| 2008 | -$93M | -45.9% | -$94M | $-96.09 | -3541.8% | -3583.5% |
| 2007 | -$63M | -10.9% | -$66M | $-68.45 | -8545.8% | -8912.0% |
| 2006 | -$57M | +16.8% | -$59M | $-90.03 | - | - |
| 2005 | -$69M | -49.9% | -$71M | $-108.31 | - | - |
| 2004 | -$46M | -64.8% | -$45M | $-85.96 | -26551.4% | -26211.6% |
| 2003 | -$28M | - | -$28M | $-44.65 | -2137.9% | -2169.8% |
Download Data
Export MDGL earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into MDGL consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MDGL — Frequently Asked Questions
Quick answers to the most common questions about buying MDGL stock.
What is MDGL earnings per share (EPS)?
MDGL trailing twelve-month (TTM) diluted EPS is $-10.66, reflecting +41.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2003 to 2025 is available in the table on this page.
What is Madrigal Pharmaceuticals, Inc.'s net income?
Madrigal Pharmaceuticals, Inc. (MDGL) trailing twelve-month net income is $-309M as of 2025. Earnings grew +41.3% year-over-year.
Is MDGL profitable?
MDGL is not currently profitable on a TTM basis, reporting a net loss of $-309M. Net margin is -30.1%. Investors should monitor for a return to profitability.
What is MDGL's earnings growth rate?
MDGL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2003 to 2025.
What are MDGL's profit margins?
Madrigal Pharmaceuticals, Inc. net profit margin is -30.1%, operating margin is -31.3%, and gross margin is +94.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -42.5%.
Is MDGL growing earnings?
Yes, MDGL earnings are accelerating — EPS growth of +41.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-309M. Earnings momentum is strengthening.
What was MDGL's best earnings year?
Madrigal Pharmaceuticals, Inc.'s highest annual net income on record is $79M, achieved in fiscal year 2009. Earnings history on this page spans 2003 to 2025 and includes all annual and quarterly figures.
What were MDGL's earnings last quarter?
MDGL's most recent reported quarter was Q1 2026. Net income was $-94M with diluted EPS of $-3.25. For a full breakdown of all quarters, see the quarterly earnings table on this page.